Postcard from Palm Springs 2024
The Postcards are a series of short videos aimed at non-scientists that convey the major themes, scientific breakthroughs, and clinical trial updates from each year’s Huntington’s Disease Therapeutics Conference held (most usually) in Palm Spring ...Read More
Evotec and CHDI Foundation extend strategic drug discovery collaboration in Huntington’s disease
Hamburg, Germany, 28 May 2024: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) has announced the extension of its 20-year collaboration with CHDI Foundation, Inc. (“CHDI”) ...Read More
Huntington Study Group and CHDI Foundation collaborate on Enroll-HD
Rochester and New York City, New York, July 25, 2023 – HSG Clinical Research, Inc.—the Huntington Study Group’s clinical research organization (CRO) and wholly owned subsidiary (collectively referred to here as HSG)—has begun ...Read More
Huntington’s Disease Image Harmonization Consortium secures new member and funding to complete large-scale analysis of brain changes using IXIQ.Ai
New York, NY / London, UK, July, 12th 2023; The Huntington’s Disease Imaging Harmonization (HD-IH) Consortium, founded last year to conduct an unprecedented harmonization analysis of more than 6,000 participant-visit magnetic resonance images (MRIs ...Read More
What is CHDI?
European Medicines Agency issues qualification opinion that Enroll-HD can provide data and infrastructure support for post-authorization monitoring of medical products for Huntington’s disease
New York, NY, September 21, 2022; The European Medicines Agency (EMA) has issued a qualification opinion that details facets of the Enroll-HD registry, core observational study, and clinical research platform that are especially suited to post-author ...Read More
Call to Action – New consortium will use artificial intelligence technology to conduct large-scale analysis of brain changes in Huntington’s disease
New York, NY / London, UK, September 21 2022; IXICO, uniQure, PTC Therapeutics, Inc, and CHDI Foundation have formed the Huntington’s Disease Imaging Harmonization Consortium (HD-IH) to better understand the structural brain changes that occur over ...Read More
Postcard from Palm Springs 2022
The Postcards are a series of short videos aimed at non-scientists that convey the major themes, scientific breakthroughs, and clinical trial updates from each year’s Huntington’s Disease Therapeutics Conference held (most usually) in Palm Spring ...Read More
Alchemab and Medicines Discovery Catapult to develop landmark novel antibody therapy for Huntington’s disease
LONDON--(BUSINESS WIRE)--Alchemab, a biotech company developing novel therapeutics for patients with hard-to-treat diseases by harnessing the power of naturally protective antibodies, has been awarded a UK ...Read More
Molecular Design Platform Accelerating Research For Huntington’s Disease
OpenEye Scientific and CHDI Foundation Announce Collaboration on Small-Molecule Computational Research for Huntington’s Disease SANTA FE, N.M., & NEW YORK, N.Y. – July 28, 2020 – OpenEye Scientific (OpenEye) ...Read More